Roche is to sell three of its products to Icelandic generics maker Actavis in a move which the Swiss drugs giant says underlines its strategy of “focusing on core products from its innovation-driven pharmaceutical and diagnostic divisions”.

The Basel-headquartered firm is transferring the rights, “with some territorial exceptions” to the cardiovascular drugs Bezalip (bezafibrate) and Rapilysin (reteplase) and the dermatology product Neotigason (acitretin) to Actavis, but will continue to distribute them in Latin America for the Icelandic firm. Financial details of the transaction, which is expected to close at the end of the year or early 2008, were not disclosed but Roche noted that the three products had combined sales of 140 million Swiss francs in 2006, around $117 million.

– Meantime Roche has filed an investigational new drug application with the US Food and Drug Administration for an antibody developed under the company’s collaboration with Denmark’s Genmab.

Genmab said it will receive an undisclosed milestone payment and the firm’s chief executive Lisa Drakeman noted that the candidate will be the second antibody produced under the collaboration to enter the clinic.